7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      ADAM9 silencing inhibits breast tumor cell invasion in vitro.

      Biochimie
      ADAM Proteins, genetics, metabolism, Breast Neoplasms, enzymology, Cell Adhesion, Cell Line, Tumor, Cell Proliferation, Female, Humans, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Membrane Proteins, Neoplasm Invasiveness, Neoplasm Metastasis, RNA Interference, RNA, Small Interfering

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          ADAM9 (A Disintegrin And Metalloproteinase 9) is a member of the ADAM protein family which contains a disintegrin domain. This protein family plays key roles in many physiological processes, including fertilization, migration, and cell survival. The ADAM proteins have also been implicated in various diseases, including cancer. Specifically, ADAM9 has been suggested to be involved in metastasis. To address this question, we generated ADAM9 knockdown clones of MDA-MB-231 breast tumor cells using silencing RNAs that were tested for cell adhesion, proliferation, migration and invasion assays. In RNAi-mediated ADAM9 silenced MDA-MB-231 cells, the expression of ADAM9 was lower from the third to the sixth day after silencing and inhibited tumor cell invasion in matrigel by approximately 72% when compared to control cells, without affecting cell adhesion, proliferation or migration. In conclusion, the generation of MDA-MB-231 knockdown clones lacking ADAM9 expression inhibited tumor cell invasion in vitro, suggesting that ADAM9 is an important molecule in the processes of invasion and metastasis. Copyright © 2013 Elsevier Masson SAS. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article